No Data
No Data
BTIG Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $5
BTIG analyst Kaveri Pohlman maintains $Nuvation Bio(NUVB.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 28.5% and a total
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Nuvation Bio (NUVB)
H.C. Wainwright Maintains Nuvation Bio(NUVB.US) With Buy Rating, Maintains Target Price $8
H.C. Wainwright analyst Robert Burns maintains $Nuvation Bio(NUVB.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 28.2% and
Buy Rating Affirmed for Nuvation Bio Amid Promising Taletrectinib Trials and Orphan Drug Designation
We Think Nuvation Bio (NYSE:NUVB) Can Easily Afford To Drive Business Growth
Nuvation Bio(NUVB.US) Director Buys US$825.35K in Common Stock
$Nuvation Bio(NUVB.US)$ Director Cui Xiangmin purchased 277.9K shares of common stock on Jun 25, 2024 at an average price of $2.97 for a total value of $825.35K.Source: Announcement What is statement
Jaguar8 : Wow 2 straight days of buying if I remember
TrytosaveabitOP : A little over 2 million worth in 5 days or so! WooHoo! Hehehe
Jaguar8 TrytosaveabitOP: Well with its promising 91% tumor reduction in NSCLC study, he is confident about it. 91% is a wow
TrytosaveabitOP Jaguar8: Oh yeah! You know I’m in total agreement with you here!
Jaguar8 TrytosaveabitOP: And we should be confident about it too with his loading
View more comments...